{"id":22191,"date":"2023-02-06T12:06:00","date_gmt":"2023-02-06T04:06:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22191"},"modified":"2025-01-20T12:09:48","modified_gmt":"2025-01-20T04:09:48","slug":"gsk-reports-strong-q4-and-full-year-2022-financials-amid-strategic-shift","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22191","title":{"rendered":"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift"},"content":{"rendered":"\n

UK-based GlaxoSmithKline plc (NYSE: GSK<\/a>) has released its financial report for Q4 and the full-year 2022, revealing strong performance since spinning off its consumer health division last year. The strategic shift in focus to vaccines and specialty medicines produced 13% year-on-year growth in global sales to GBP 29.3 billion (USD 36.32 billion). In Q4, sales were down 3% to GBP 7.38 billion (USD 9.15 billion). GSK issued guidance for 2023 revenue growth to increase by between 6%-8%, excluding COVID-19-related products.<\/p>\n\n\n\n

CEO’s Perspective and New Product Growth<\/strong>
CEO Emma Walmsley described the performance as \u201coutstanding,\u201d attributing much of the success to new products. \u201cWe’ve had over 20 new approvals in the last 5 years, now representing nearly one-third of our 2022 sales,\u201d she noted. GSK also boasts a robust pipeline with 18 products at the Phase III or registration stages.<\/p>\n\n\n\n

Business Unit Performance<\/strong>
Over the past 12 months, Specialty Medicines generated GBP 11.3 billion in sales, up 29%. Within this segment, HIV drugs rose 12%, oncology 17%, immuno-inflammation and other specialty drugs 20%, and GSK\u2019s COVID-19 therapy Xevudy (sotrovimab) generated GBP 2.3 billion (USD 2.85 billion). Vaccines produced GBP 7.9 billion (USD 9.79 billion) in revenues with an 11% YOY growth, driven by the shingles vaccine Shingrix, which contributed GBP 3 billion (USD 3.72 billion) and 60% YOY growth. General Medicines generated GBP 10.1 billion in sales, up 1% YOY.<\/p>\n\n\n\n

China Market Highlights<\/strong>
Although market specifics were not broken out, China was cited as making several positive contributions. Shingrix launched in China in June 2020, with strong uptake reported during 2022. Speaking during the earnings conference call, Chief Commercial Officer Luke Miels noted that \u201cas China starts to normalize, the potential for [Shingrix] over the next couple of years remains very, very sizeable.\u201d Additionally, reimbursement coverage under China\u2019s National Reimbursement Drug List (NRDL) was cited as a positive for lupus therapy Benlysta (belimumab) and asthma drug Trelegy (vilanterol, fluticasone furoate, umeclidinium).-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,278,914,12],"class_list":["post-22191","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-glaxosmithkline","tag-nyse-gsk","tag-vaccine"],"yoast_head":"\nGSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year 2022, revealing strong performance since spinning off its consumer health division last year. The strategic shift in focus to vaccines and specialty medicines produced 13% year-on-year growth in global sales to GBP 29.3 billion (USD 36.32 billion). In Q4, sales were down 3% to GBP 7.38 billion (USD 9.15 billion). GSK issued guidance for 2023 revenue growth to increase by between 6%-8%, excluding COVID-19-related products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22191\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22191\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-06T04:06:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-20T04:09:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22191#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22191\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift\",\"datePublished\":\"2023-02-06T04:06:00+00:00\",\"dateModified\":\"2025-01-20T04:09:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22191\"},\"wordCount\":309,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"GlaxoSmithKline\",\"NYSE: GSK\",\"Vaccine\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22191#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22191\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22191\",\"name\":\"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-06T04:06:00+00:00\",\"dateModified\":\"2025-01-20T04:09:48+00:00\",\"description\":\"UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year 2022, revealing strong performance since spinning off its consumer health division last year. The strategic shift in focus to vaccines and specialty medicines produced 13% year-on-year growth in global sales to GBP 29.3 billion (USD 36.32 billion). In Q4, sales were down 3% to GBP 7.38 billion (USD 9.15 billion). GSK issued guidance for 2023 revenue growth to increase by between 6%-8%, excluding COVID-19-related products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22191#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22191\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22191#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift - Insight, China's Pharmaceutical Industry","description":"UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year 2022, revealing strong performance since spinning off its consumer health division last year. The strategic shift in focus to vaccines and specialty medicines produced 13% year-on-year growth in global sales to GBP 29.3 billion (USD 36.32 billion). In Q4, sales were down 3% to GBP 7.38 billion (USD 9.15 billion). GSK issued guidance for 2023 revenue growth to increase by between 6%-8%, excluding COVID-19-related products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22191","og_locale":"en_US","og_type":"article","og_title":"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22191","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-06T04:06:00+00:00","article_modified_time":"2025-01-20T04:09:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22191#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22191"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift","datePublished":"2023-02-06T04:06:00+00:00","dateModified":"2025-01-20T04:09:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22191"},"wordCount":309,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","GlaxoSmithKline","NYSE: GSK","Vaccine"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22191#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22191","url":"https:\/\/flcube.com\/?p=22191","name":"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-06T04:06:00+00:00","dateModified":"2025-01-20T04:09:48+00:00","description":"UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year 2022, revealing strong performance since spinning off its consumer health division last year. The strategic shift in focus to vaccines and specialty medicines produced 13% year-on-year growth in global sales to GBP 29.3 billion (USD 36.32 billion). In Q4, sales were down 3% to GBP 7.38 billion (USD 9.15 billion). GSK issued guidance for 2023 revenue growth to increase by between 6%-8%, excluding COVID-19-related products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22191#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22191"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22191#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22191"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22191\/revisions"}],"predecessor-version":[{"id":22192,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22191\/revisions\/22192"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}